Both adaptive ERK and protein kinase B (AKT) reactivation have been observed in a wide range of targeted therapies against many cancers, including EGFR, HER2, MEK, RAF, and PI3K inhibition in non‐small cell lung cancer (NSCLC), renal cell carcinoma, melanoma, colorectal cancer, and prostate cancer respectively [18, 19, 20, 21, 22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.